Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 30, 2016Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical PsychopharmacologyOpen Access

Comment on FDA's Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

View Full Paper
Ask AI
Bookmark
Share

Authors

RTReji ThomasMÇMesut ÇetinGBGlen B. Baker

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Thomas et al. (2016) studied this question.

synapsesocial.com/papers/6a227e448a4701dbb7913701https://doi.org/10.5455/bcp.20161027122045
View Full Paper
Ask AI
Bookmark
Share